Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 1 (1)
P 4 (1)

Trial Status

Recruiting2
Unknown1
Enrolling By Invitation1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06611072Not ApplicableRecruiting

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

NCT05655273Phase 4Enrolling By Invitation

Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients

NCT05364411Not ApplicableRecruiting

HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC

NCT03024957Phase 1UnknownPrimary

Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity

Showing all 4 trials

Research Network

Activity Timeline